Aridis Pharmaceuticals, Inc.

About Aridis Pharmaceuticals, Inc.

Aridis Pharmaceuticals, Inc. is a late-stage clinical development biopharmaceutical company focused on creating transformative, first-in-class anti-infectives for life-threatening viral and bacterial respiratory infections. Their mission is to combat global health threats like antibiotic resistance and viral pandemics through innovative therapies derived from proprietary technology platforms.

Products & Services

AR-301 (Tosatoxumab/SalvecinTM):A fully human monoclonal IgG1 antibody targeting S. aureus alpha-toxin to treat pneumonia caused by MRSA and MSSA.

AR-320 (Suvratoxumab):A fully human monoclonal IgG1 antibody for pre-emptive treatment of S. aureus colonized, mechanically ventilated ICU patients, targeting alpha-toxin with an extended half-life.

AR-501 (Panaecin™):An inhalable small molecule anti-infective (gallium citrate) that starves bacteria of iron, effective against antibiotic-resistant bacteria for cystic fibrosis treatment.

AR-701 (COVID-19 mAb):Multiple fully human IgG1 monoclonal antibodies targeting conserved regions of SARS-CoV-2 envelope proteins, designed for broad coverage of variants.

AR-401:A preclinical monoclonal antibody program to treat infections caused by Gram-negative bacterium Acinetobacter baumannii.

Out-licensed Products (AR-105, AR-101, AR-201):Previously developed products licensed to other entities, targeting various infectious diseases.

Specialties

Monoclonal Antibodies (mAbs) Anti-Infectives Antibiotic Resistance (AMR) Viral Pandemics Respiratory Infections Human Immune Response Mining (MabIgX Technology)

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Equity Offering T: - FT: Equity Offering	A: 2000000 MR: - FA: $2 million FAN: 2000000	D: 2023-08-02 FD: 2023-08-02	-
2	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 2280000 MR: - FA: 2.28 million FAN: 2280000	D: 2023-03-14 FD: 2023-03-14	-

Equity Offering Latest

2023-08-02

$2.0M

Registered Direct Offering 2023-03-14

$2.3M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

V

Vu L. Truong

CEO

H

Hasan Jafri

M.D.

F

Fred Kurland

Chief Financial Officer

S

Steven Chamow

Ph.D.

E

Elizabeth Leininger

Ph.D.

J

Jeffrey J. Fessler

Partner

View 15 more team members with Pro

Unlock Full Team Directory

Recent News